Pharma & Biotech

For Replimune and its investors, 2026 is shaping up to be a defining period. After a significant regulatory setback in...

While Redcare Pharmacy shares continue their prolonged decline, having shed more than 60% from their December peak, a significant development...

The battle for dominance in the lucrative weight-loss medication sector has entered a new phase of competition. Novo Nordisk, the...

The fate of German biotech firm CureVac hangs in the balance as shareholders prepare for a landmark decision that could...

Johnson & Johnson's equity is demonstrating remarkable momentum, advancing for five consecutive trading sessions with a notable surge in volume...

The telehealth sector faces increasing regulatory scrutiny, and Hims & Hers Health, Inc. is making strategic moves to navigate these...

Biopharmaceutical firm Clearside Biomedical finds itself navigating turbulent financial waters as it implements a comprehensive strategic transformation. The company's latest...

Sana Biotechnology's stock is experiencing dramatic price swings that highlight investor uncertainty. Following a steep 19% decline over ten trading...

Pfizer's recent $7 billion acquisition of biotechnology firm Metsera has triggered a wave of market skepticism rather than celebration. The...

Exelixis has ignited investor enthusiasm by reporting quarterly results that significantly exceeded market forecasts, coupled with the announcement of a...